285 related articles for article (PubMed ID: 27544755)
1. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
Kim EH; Jang H; Shin D; Baek SH; Roh JL
Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
[TBL] [Abstract][Full Text] [Related]
2. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
Kim EH; Jang H; Roh JL
Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
[TBL] [Abstract][Full Text] [Related]
3. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
Roh JL; Kim EH; Jang H; Shin D
Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
[TBL] [Abstract][Full Text] [Related]
4. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
5. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
[TBL] [Abstract][Full Text] [Related]
6. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
Shin D; Kim EH; Lee J; Roh JL
Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
[TBL] [Abstract][Full Text] [Related]
7. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
Shin D; Kim EH; Lee J; Roh JL
Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
[TBL] [Abstract][Full Text] [Related]
8. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
Kim EH; Baek S; Shin D; Lee J; Roh JL
Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
[TBL] [Abstract][Full Text] [Related]
9. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.
Roh JL; Kim EH; Park JY; Kim JW; Kwon M; Lee BH
Oncotarget; 2014 Oct; 5(19):9227-38. PubMed ID: 25193861
[TBL] [Abstract][Full Text] [Related]
10. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
Roh JL; Kim EH; Jang H; Shin D
Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
[TBL] [Abstract][Full Text] [Related]
11. Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer.
Roh JL; Jang H; Kim EH; Shin D
Antioxid Redox Signal; 2017 Jul; 27(2):106-114. PubMed ID: 27733046
[TBL] [Abstract][Full Text] [Related]
12. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
Roh JL; Park JY; Kim EH; Jang HJ
Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin.
Roh JL; Kim EH; Park JY; Kim JW
Mol Cancer Ther; 2015 Aug; 14(8):1907-15. PubMed ID: 26063766
[TBL] [Abstract][Full Text] [Related]
14. Wogonin potentiates cisplatin-induced cancer cell apoptosis through accumulation of intracellular reactive oxygen species.
He F; Wang Q; Zheng XL; Yan JQ; Yang L; Sun H; Hu LN; Lin Y; Wang X
Oncol Rep; 2012 Aug; 28(2):601-5. PubMed ID: 22665077
[TBL] [Abstract][Full Text] [Related]
15. Wogonin-enhanced reactive oxygen species-induced apoptosis and potentiated cytotoxic effects of chemotherapeutic agents by suppression Nrf2-mediated signaling in HepG2 cells.
Qian C; Wang Y; Zhong Y; Tang J; Zhang J; Li Z; Wang Q; Hu R
Free Radic Res; 2014 May; 48(5):607-21. PubMed ID: 24666416
[TBL] [Abstract][Full Text] [Related]
16. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer.
Kim EH; Shin D; Lee J; Jung AR; Roh JL
Cancer Lett; 2018 Sep; 432():180-190. PubMed ID: 29928961
[TBL] [Abstract][Full Text] [Related]
17. Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins.
Yang L; Wang Q; Li D; Zhou Y; Zheng X; Sun H; Yan J; Zhang L; Lin Y; Wang X
Apoptosis; 2013 May; 18(5):618-26. PubMed ID: 23371323
[TBL] [Abstract][Full Text] [Related]
18. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
[TBL] [Abstract][Full Text] [Related]
19. Wogonin reverses multi-drug resistance of human myelogenous leukemia K562/A02 cells via downregulation of MRP1 expression by inhibiting Nrf2/ARE signaling pathway.
Xu X; Zhang Y; Li W; Miao H; Zhang H; Zhou Y; Li Z; You Q; Zhao L; Guo Q
Biochem Pharmacol; 2014 Nov; 92(2):220-34. PubMed ID: 25264278
[TBL] [Abstract][Full Text] [Related]
20. Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway.
Wu S; Zhang T; Du J
Drug Des Devel Ther; 2016; 10():3471-3481. PubMed ID: 27822011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
